In a report released today, Yaron Werber from TD Cowen maintained a Hold rating on Genmab (GMAB – Research Report). The company’s shares closed yesterday at $19.69. Leverage the power of ...

TD Cowen analyst Joseph C Giordano maintained a Hold rating on Cognex (CGNX – Research Report) today and set a price target of $38.00. The company’s shares closed yesterday at $39.25.

today announced that company management will participate in the 45 th Annual TD Cowen Health Care Conference from March 3-5 in Boston, MA. Management will participate in a fireside chat on Tuesday ...

Investing.com -- TD Cowen downgraded Restaurant Brands International (NYSE:QSR) to Hold from Buy, citing valuation concerns and increasing risks to its Burger King and Tim Hortons brands.

TD Cowen upgraded shares of CRISPR Therapeutics (NASDAQ:CRSP – Free Report) from a sell rating to a hold rating in a research note issued to investors on Wednesday, MarketBeat reports.

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in the 45th Annual TD Cowen Health Care ...

My name is Gautam Khanna. I'm the research analyst at TD Cowen. Always feel free to reach out to me if you have any questions. We're very pleased to have with us the Chief Financial Officer of ...

Shares of CRNX stock opened at $35.21 on Tuesday. The business has a 50-day moving average of $46.12 and a 200 day moving average of $51.37. Crinetics Pharmaceuticals has a 1-year low of $34.07 ...

TD Securities’ purchase of Cowen brought together balance sheet strength with the high-touch investment banking needed to service client growth. For building a combined platform that is greater than ...

today announced plans to participate in the upcoming TD Cowen 45th Annual Health Care Conference, being held in Boston, MA. Interested parties may access a live and recorded webcast of the ...